Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Factor IX for breakthrough bleeds in Hemophilia A patients on Emicizumab
NCT05281718Phase 1Completed
- Sponsor
- Tulane University
- Start
- Aug 2022
- Primary completion
- Mar 2024
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of coagulation factor ix in hemophilia A, sponsored by Tulane University. Primary endpoints: Peak Thrombin with Factor IX at 1 year, Peak Thrombin with Factor IX and recombinant porcine FVIII at 1 year and 2 more. Started Aug 2022; status: completed.
02
Drugs
coagulation factor ix
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NCT05281718.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05281718.